Glass House Brands (GLAS) Net Margin (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Net Margin of 34.85% for Q1 2026, up 12.65% quarter-over-quarter from 39.89% in Q4 2025.

Glass House Brands (GLAS) Net Margin (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Net Margin for 7 consecutive years, with 34.85% the latest figure, recorded in Q1 2026.

In Q1 2026, Net Margin changed N/A year-over-year to 34.85%; the TTM figure through Mar 2026 stood at 16.47% (changed N/A YoY), while the FY2025 annual figure was 15.91%, down 1627.0% from the prior year.
Net Margin rose to 34.85% in Q1 2026 per GLAS's latest filing, from 39.89% in the prior quarter.
Across five years, Net Margin topped out at 53.71% in Q3 2022 and bottomed at 75635558.75% in Q2 2022.
Historically, Net Margin has averaged 11965105.25% across 5 years, with a median of 37.37% in 2026.
Annual changes were most pronounced in 2022 — Net Margin slumped 2000000000 bps — and 2024, when it soared 2000000000 bps.
Glass House Brands' Net Margin stood at 98.73% in 2022, then slumped by 44583166 bps to 44015234.8% in 2023, then soared by 100 bps to 22.12% in 2024, then sank by 280 bps to 39.89% in 2025, then advanced by 13 bps to 34.85% in 2026.
Business Quant data shows GLAS's Net Margin at 34.85% in Q1 2026, 39.89% in Q4 2025, and 26.66% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-13.91%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	9.28%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	42.51%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Glass House Brands	830.21 Mn	811.66 Mn	15.77 Mn	-8.07%

Download Data